Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34).

Manuel Alfonso Patarroyo, Alvaro Mongui, Diana I. Angel, Gina Gallego, Claudia Reyes, Paola Martinez, Felipe Guhl

Research output: Contribution to journalArticlepeer-review

Abstract

This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.
Original languageEnglish (US)
Pages (from-to)415-421
Number of pages17
JournalVaccine
Volume28
Issue number2
StatePublished - Dec 11 2009

Fingerprint Dive into the research topics of 'Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34).'. Together they form a unique fingerprint.

Cite this